Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Multiple sclerosis

Serum NfL as an MS biomarker

Nature Reviews Neurology volume 19, page 3 (2023)Cite this article

Subjects

A large real-world study has evaluated the use of serum neurofilament light chain (sNfL) as a biomarker for multiple sclerosis (MS). Levels of this protein were measured in 6,974 people with MS and 201 healthy individuals using a high-throughput immunoassay. sNfL was elevated in a significant proportion of people with MS. The levels correlated with severity of physical and cognitive disability, brain atrophy and radiological inflammatory disease activity, validating sNfL as a useful biomarker for MS.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

Original article

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Neurology http://www.nature.com/nrneurol/

    Lisa Kiani

Authors
  1. Lisa Kiani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lisa Kiani.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kiani, L. Serum NfL as an MS biomarker. Nat Rev Neurol 19, 3 (2023). https://doi.org/10.1038/s41582-022-00760-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41582-022-00760-4

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing